A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

Background: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown efficacy for reducing ... Objective: To compare risk of incident AF after initiation of GLP1-RA vs Dipeptidyl peptidase-4 ...

Background: GLP-1 receptor agonists (GLP1RA) agonists have been shown to reduce ... Compared to the control group, the GLP1RA cohort had a higher baseline risk profile (BMI: 35.1 [SD 7.6] vs. 31.0 [SD ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer ... combines this drug with AZD6234, a long-acting analogue targeting the pancreas hormone amylin, which ...

The biotech said it would use the cash to “further accelerate” a portfolio led by its GLP-1 receptor agonist MET-097 ... an injectable amylin analog that is Metsera’s answer to the sector ...

Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs ... an SGLT-2 inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA), with a ...

DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes ... annually are 72% more likely to take a GLP-1 than those earning $50,000 or less (6.8% vs. 4.0%). Perceptions around the ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes ... annually are 72% more likely to take a GLP-1 than those earning $50,000 or less (6.8% vs. 4.0%). Perceptions around the ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...